3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
28
Carcinoma, Hepatocellular
25
Colorectal Neoplasms
23
Carcinoma, Non-Small-Cell Lung
13
Melanoma
12
Stomach Neoplasms
10
Colonic Neoplasms
10
Liver Neoplasms
9
Neoplasm Metastasis
8
Squamous Cell Carcinoma of Head and Neck
7
Carcinoma, Transitional Cell
7
Carcinoma, Renal Cell
7
Uterine Cervical Neoplasms
6
Rectal Neoplasms
6
Ovarian Neoplasms
6
Diabetes Mellitus, Insulin-Dependent, 12
6
Prostatic Neoplasms
5
Lung Neoplasms
5
Gastrointestinal Stromal Tumors
5
Esophageal Neoplasms
5
Carcinoma
5
Urinary Bladder Neoplasms
4
Turcot syndrome
4
Triple Negative Breast Neoplasms
4
Small Cell Lung Carcinoma
4
Sarcoma
4
Mesothelioma
4
Endometrial Neoplasms
4
Cholangiocarcinoma
4
Carcinoma, Merkel Cell
4
Interventions
Gemcitabine
13
Albumin-Bound Paclitaxel
8
Taxes
6
130-nm albumin-bound paclitaxel
6
Fluorouracil
5
Oxaliplatin
4
dehydroftorafur
3
Radiotherapy, Intensity-Modulated
3
Radiotherapy
3
Leucovorin
3
Irinotecan
3
Losartan
2
Cisplatin
2
tocilizumab
1
selicrelumab
1
niraparib
1
irinotecan sucrosofate
1
indusatumab
1
folfirinox
1
durvalumab
1
cobimetinib
1
atezolizumab
1
X-Rays
1
Tiragolumab
1
Surgical Procedures, Operative
1
Standard of Care
1
Specimen Handling
1
S 1 (combination)
1
Resistance Training
1
Radiotherapy, Image-Guided
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Adenocarcinoma
×
Ipilimumab
×
Gastrointestinal
×
Clear all
NCT03404960
2025-10-10
Parpvax
University of Pennsylvania
Phase 1/2
Completed
104 enrolled
11 charts